Post-Therapy CT-Detected Mass in Lymphoma Patients

Lewis, Errol; Bernardino, Michael E.; Salvador, P.; Cabanillas, Fernando; Barnes, Patricia A.; Thomas, John L.

doi:10.1097/00004728-198208000-00025

Cited by 57 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There may be limitations in corroborating a CR in viscera by CT alone 20,21 and in those cases, a confirmatory biopsy may be necessary or lacking this, no CR assessment can be made.…”

Section: Visceral Disease Assessment Scoring and Definition Of Respmentioning

confidence: 99%

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Olsen

Whittaker

Kim

et al. 2011

JCO

592

518

View full text Add to dashboard Cite

Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.

show abstract

“…There may be limitations in corroborating a CR in viscera by CT alone 20,21 and in those cases, a confirmatory biopsy may be necessary or lacking this, no CR assessment can be made.…”

Section: Visceral Disease Assessment Scoring and Definition Of Respmentioning

confidence: 99%

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Olsen

Whittaker

Kim

et al. 2011

JCO

592

518

View full text Add to dashboard Cite

show abstract

“…Often these abnormalities represented fibrotic scar with no viable tumor evident [18,19]. With the increasing use of CT, more specific criteria were needed to assess the significance of residual masses.…”

Section: Discussionmentioning

confidence: 99%

Mediastinal Large Cell Lymphoma: Prognostic Significance ofCT Findings at Presentation and after Treatment

Smith¹,

Shaffer²,

Kirn

et al. 1998

Oncology

View full text Add to dashboard Cite

Objective: Primary mediastinal large cell lymphoma is a distinctive subtype of non-Hodgkin’s lymphoma. Computed tomography (CT) has become an integral part of the evaluation of these patients at presentation and after completion of therapy. The purpose of this study is to identify CT features that predict increased risk of relapse. Methods: A retrospective study of patients with primary mediastinal large cell lymphoma who underwent CT scans of the thorax. Results: Tumor volume greater than 100 ml after completion of therapy was a statistically significant predictor of increased risk of relapse (p = 0.02, Fisher exact test). Other measurements (obtained at presentation and after completion of treatment) were not statistically significant in predicting relapse. Conclusion: CT plays an important role in predicting outcome in primary mediastinal large cell lymphoma. Large residual tumor volume after completion of treatment predicts an increased risk of relapse.

show abstract

“…The incorporation of PET imaging helped to address the issue of residual masses detected after therapy, which frequently comprise inflammatory, necrotic, and fibrotic tissue rather than residual disease (14)(15)(16). This phenomenon proved especially problematic for lymphoma, for which the response assessment criteria relied solely on anatomic imaging.…”

Section: Historical Review Of Response Assessment In Solid Tumorsmentioning

confidence: 99%

Response Assessment Criteria and Their Applications in Lymphoma: Part 1

et al. 2016

View full text Add to dashboard Cite

Post-Therapy CT-Detected Mass in Lymphoma Patients

Cited by 57 publications

References 0 publications

Mediastinal Large Cell Lymphoma: Prognostic Significance ofCT Findings at Presentation and after Treatment

Response Assessment Criteria and Their Applications in Lymphoma: Part 1

Contact Info

Product

Resources

About